MET and non-small cell lung carcinoma: Teliso-V demonstrated a promising ORR in patients with previously treated c-Met-overexpressing non-squamous EGFR-wild-type NSCLC (36.5%; 52.2% in the c-Met-high group and 24.1% in the c-Met-intermediate group).